GD2CART for Osteosarcoma or Neuroblastoma

Contact

If you are interested in participating in the study or want to learn more, please get in touch.

This study is now recruiting. Learn more about enrolling here.

Description

This study enrolls patients that have been diagnosed with osteosarcoma or neuroblastoma that has come back (relapsed) or has not responded to standard treatments (refractory). This study involves an investigational cellular therapy called GD2CART. The study will be testing different doses of the study drug to find the safest dose.

Eligibility and criteria

IRB Number:

22-020029

Eligible age range:

1 years - 40 years

Clinical trial phase:

Phase I

Official title:

PED-CITN-02: GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor Exposure - (NCT04539366)

What to expect

Participants in this research will:

Have an electrocardiogram (ECG) and echocardiogram (ECHO) before receiving the cellular therapy
Undergo apheresis to remove white blood cells (called T Cells) from their blood
Receive the cellular therapy called GD2CART via infusion. This is manufactured from participant's T Cells.
Complete frequent clinic visits at CHOP
Have research blood tests
Have extra or leftover tissue collected if they have a biopsy as part of regular cancer care

Related specialties

Solid Tumor Program

Cancer Center

Cancer Immunotherapy Program

Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.

Find a research study

Innovation and your child

Find research studies